key: cord-0971254-pzl8r5yc
authors: Jamthikar, Ankush D.; Gupta, Deep; Puvvula, Anudeep; Johri, Amer M.; Khanna, Narendra N.; Saba, Luca; Mavrogeni, Sophie; Laird, John R.; Pareek, Gyan; Miner, Martin; Sfikakis, Petros P.; Protogerou, Athanasios; Kitas, George D.; Kolluri, Raghu; Sharma, Aditya M.; Viswanathan, Vijay; Rathore, Vijay S.; Suri, Jasjit S.
title: Cardiovascular risk assessment in patients with rheumatoid arthritis using carotid ultrasound B-mode imaging
date: 2020-08-28
journal: Rheumatol Int
DOI: 10.1007/s00296-020-04691-5
sha: 9c8b652b179753db0cc67074ab97f1318a9c61d4
doc_id: 971254
cord_uid: pzl8r5yc

Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease that affects synovial joints and has various extra-articular manifestations, including atherosclerotic cardiovascular disease (CVD). Patients with RA experience a higher risk of CVD, leading to increased morbidity and mortality. Inflammation is a common phenomenon in RA and CVD. The pathophysiological association between these diseases is still not clear, and, thus, the risk assessment and detection of CVD in such patients is of clinical importance. Recently, artificial intelligence (AI) has gained prominence in advancing healthcare and, therefore, may further help to investigate the RA-CVD association. There are three aims of this review: (1) to summarize the three pathophysiological pathways that link RA to CVD; (2) to identify several traditional and carotid ultrasound image-based CVD risk calculators useful for RA patients, and (3) to understand the role of artificial intelligence in CVD risk assessment in RA patients. Our search strategy involves extensively searches in PubMed and Web of Science databases using search terms associated with CVD risk assessment in RA patients. A total of 120 peer-reviewed articles were screened for this review. We conclude that (a) two of the three pathways directly affect the atherosclerotic process, leading to heart injury, (b) carotid ultrasound image-based calculators have shown superior performance compared with conventional calculators, and (c) AI-based technologies in CVD risk assessment in RA patients are aggressively being adapted for routine practice of RA patients.

Rheumatoid arthritis (RA) is a chronic inflammatory disease that not affects only synovial joints but also has several extra-articular involvements, including those related to the skin, eyes, heart, lungs, kidneys, and other organs [1, 2] . It affects ~ 1% of the global population, with a higher prevalence in females when compared with males [3, 4] . Cardiovascular disease (CVD) is a common manifestation in RA patients with a two-to three-fold higher risk of cardiovascular events and mortality compared with a normal population [5] . However, this increased risk is not entirely explained by conventional risk factors [6] . Current statistically derived CVD risk calculators use conventional risk factors alone [7] [8] [9] , are not suitable for RA patients, and they either underestimate or overestimate the risk [10] [11] [12] . This may be because of the paradoxical behavior of some of the conventional risk factors such as body mass index, low-density lipoprotein, high-density lipoprotein, and total cholesterol in RA [13, 14] . Despite this lack of clarity, the guidelines by the European League Against Rheumatism (EULAR) recommend aggressive control of these conventional risk factors [15, 16] . Recent attempts were made to improve the CVD risk assessment in the RA population, including the development of "RA-specific risk factors" in the CVD risk calculators [17] [18] [19] [20] . However, such calculators could not provide adequate improvement in risk prediction and reportedly still underestimated or overestimated CVD risk in RA patients [21, 22] .

To provide a better CVD risk assessment in RA, a pathophysiological association between these diseases should be understood, as this would help in refining CVD risk predictors in RA patients [23] . Atherosclerosis, a common phenomenon in RA [24, 25] , can be adequately monitored using imaging modalities such as magnetic resonance imaging [26] , computed tomography [27], optical coherence tomography [28] , and ultrasound [29] . Each of these imaging modalities offers unique information about morphological variations in atherosclerotic plaque. Ultrasound imaging, specifically in carotid arteries, is a comparatively low-cost, non-invasive, radiation-free, and easy-to-use imaging modality that is widely adopted in preventive cardiovascular and clinical vascular practices [29, 30] . The image-based phenotypes of carotid ultrasound, such as carotid intima-media thickness (cIMT) and carotid plaque, are considered surrogate markers of coronary artery disease and have been used for preventive CVD risk assessments in several studies [31] [32] [33] [34] . These image-based phenotypes indicate the morphological variations in the atherosclerotic plaque and are associated with the inflammatory markers of RA [35] [36] [37] [38] . Patients with RA have elevated cIMT and have more plaque area (PA) when compared with non-RA patients [39] [40] [41] . Thus, the inclusion of these image-based phenotypes in risk prediction models may improve the CVD risk assessments of RA patients. Recent studies have combined the effect of these image-based phenotypes with conventional risk factors, including pro-inflammatory markers like erythrocyte sedimentation rate (ESR), to perform CVD risk assessment [42] [43] [44] . Such integrated risk calculators have demonstrated better CVD risk stratification when compared to traditional CVD risk calculators in non-RA patients [42, 43, 45] .

Besides these statistically derived CVD risk calculators, artificial intelligence (AI)-based techniques are also penetrating several medical imaging and risk assessment applications [46] [47] [48] [49] [50] [51] [52] [53] [54] . AI-based algorithms such as machine learning (ML) methods provide a better CVD risk assessment when compared with statistically derived conventional risk calculators [51, 55, 56] . So far, AI algorithms have been used for CVD risk assessment in the non-RA population, and their potential still needs to be evaluated in RA cohorts. However, AI is well adapted for RA screening and diagnosis [57] [58] [59] [60] . This review provides an insight into how the AI-based algorithms can be used for CVD risk assessment in RA patients. There are three aims of this review: (1) to summarize the pathophysiological pathways that link RA with CVD; (2) to identify several traditional and carotid ultrasound image-based CVD risk calculators for RA patients, and (3) to provide an understanding of the role of artificial intelligence in CVD risk assessment in RA patients. Figure 1 shows a flow diagram indicating the search strategy for this narrative review. To write a comprehensive narrative review, it is essential to select at least two credible databases that provide high-quality peer-reviewed articles [61] . This review is the outcome of several searches in the PubMed and Web of Science databases using keywords such as "cardiovascular diseases" AND "risk assessment" AND "rheumatoid arthritis," "carotid atherosclerosis" AND "rheumatoid arthritis," "non-invasive imaging" AND "rheumatoid arthritis," "carotid ultrasound" AND "rheumatoid arthritis," "carotid intima-media thickness" OR "carotid plaque" AND "inflammatory markers," "carotid atherosclerosis" AND "erythrocyte sedimentation rate" OR "C reactive protein," "machine learning" AND "rheumatoid arthritis," and "machine learning" AND "cardiovascular risk assessment" AND "rheumatoid arthritis." The availability of all these keywords in the abstract and the full text was investigated to select the relevant articles. Peer-reviewed articles published in the last 10 years were then given priority. Citations from the published articles were also shortlisted for this review. All these articles were subsequently filtered by the expert co-authors to select only those that met the objectives of this review, leading to 120 articles.

The pathophysiological association between RA and CVD can be explained in two stages: (1) the role of traditional risk factors, and (2) direct vascular damage. Inflammation plays a pivotal role in both of these stages [24] .

The right-hand panel of Fig. 2 explains the pathophysiological association between RA and CVD via four pathways [I(a)-I(d)] governed by traditional risk factors such as hypertension, proatherogenic dyslipidemia, insulin resistance, and obesity. Patients with RA are generally found with pro-inflammatory cytokines such as interleukin (IL) 1, IL-6, and tumor necrosis factor α (TNF-α) [62] . These pro-inflammatory cytokines are found in the synovium, which triggers a systemic inflammatory response, and may result in damage to the vascular endothelial cells [62] . Nitric oxide (NO) and cyclooxygenase-1 are two essential components required to maintain the healthy endothelium, which is inhibited by TNF-α and IL-6, thereby resulting in endothelial cell damage [23, 62] . Inhibiting endothelial NO leads to arterial stiffness [63] and is further associated with an increase in peripheral vascular resistance (PVR) [64] , thus leading to hypertension in RA patients. Additionally, several medications used to treat RA, such as disease-modifying antirheumatic drugs (DMARDs) leflunomide and cyclosporine, glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and cyclooxygenase II inhibitors (Cox IBs) may also be involved in the development of hypertension in RA patients [65, 66] .

Another pathophysiological link between RA and CVD is proatherogenic dyslipidemia [67] . Nearly 55%-65% of RA patients have proatherogenic dyslipidemia [68] . In non-RA patients, increased CVD risk is associated with elevated levels of low-density cholesterol (LDL-c), total cholesterol, and reduced high-density lipoprotein cholesterol (HDL-c). However, in RA patients, low levels of total cholesterol (TC), low levels of LDL-c, and suppressed levels of HDL-c have been reported. This condition is known as "the lipid paradox" [14] . Highly suppressed HDL levels in RA patients are "proatherogenic" [14] . Furthermore, RA patients show high atherogenic index levels despite low lipid levels. The atherogenic index is calculated as a ratio of TC: HDL-c, and it may vary according to their levels [14] . Apolipoprotein B (Apo B) is a major apolipoprotein in LDL, and several studies have indicated an increase in the ratio of Apo B: Apo A in RA patients [14] . A combination of low TC, LDL-c, and suppressed HDL-c levels with a high atherogenic index and a high ApoB:ApoA ratio behaves as proatherogenic dyslipidemia [14, 69] . Long-standing proatherogenic dyslipidemia causes atherosclerosis and, eventually, CVD.

Rheumatoid cachexia is another important RA-specific characteristic that increases CVD risk [70] . It is characterized by significantly increased adiposity and reduced muscle mass while one maintains their bodyweight [71] . The pathophysiology [shown in "pathway-I (c)"] behind R. cachexia can be explained in two ways: (1) It is characterized by the reduction of muscle mass that is largely due to increased inflammatory cytokines (particularly TNF-α) by activating the transcriptional nuclear factor-kappa B cells (NF-kB) pathway and promoting the ubiquitin pathway, which causes catabolism/proteolysis (muscle protein breakdown) [72, 73] . (2) Central obesity or abdominal obesity is present in 20-57% of women and 80-90% of men. This causes visceral adiposity in RA, which has an additional adverse impact on CVD [74] . On the other hand, increased adiposity also induces the production of inflammatory cytokines in RA, which further worsens this [75] . This syndrome may be explained in the triad of increased adiposity reduced muscle mass and low body mass index (BMI).

Epidemiological studies have suggested a strong association between insulin resistance (IR), metabolic syndrome, and RA [76, 77] [shown in "pathway-I (d)" in the dark green-dotted box]. Inflammation plays a crucial role in these three conditions [78] . In patients with RA, IR serves as an independent prognostic risk factor that signifies the presence of subclinical atherosclerosis; it is determined by carotid intimal thickness (cIMT) and is measured by carotid ultrasonography [79] . Longstanding inflammation due to RA promotes oxidative stress, endothelial dysfunction, and atherosclerosis in this population [24] .

In RA, the activation of T-cells and mast cells increases the production of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α. These pro-inflammatory cytokines stimulate endothelial cells (ECs) and smooth muscle cells (SMCs) in subendothelium [80] (1) by expressing cell adhesion molecules such as vascular cell adhesion molecule 1 (VCAM) and the "intercellular adhesion molecule" (ICAM) [80] and (2) by producing chemokines, including monocyte chemoattractant protein (MCP) and macrophage colony-stimulating factor (M-CSF). The activation of endothelial cells allows the migration of LDL-c into the sub-endothelial layer, where it becomes oxidized and triggers the inflammatory response for the recruitment of immune cells such as T lymphocytes and monocytes in the intimal layer. Once they enter the intimal layer, monocytes are transformed into macrophages, and they then take up the oxidized LDL-c to become foam cells. The completion of this complex process then leads to the formation of atherosclerotic plaque. Macrophages also trigger the migration of smooth muscle cells from tunica media to tunica intima and initiate their proliferation. The SMCs form a thin fibrous cap to prevent the encroachment of atherosclerotic plaque towards the lumen. However, over time, pro-inflammatory cytokines, enzymes, and free radicals cause fibrous cap erosion and make the plaque vulnerable for rupture. The amplification of the inflammatory response results in the acceleration of plaque formation, eventually leading to plaque rupture and thrombotic events, which damage the blood vessels. Pathway II of Fig. 2 represents this process.

Over the last decade, several CVD risk assessment calculators have been developed, very few of which are recommended by the cardiovascular risk management guidelines [9, 81, 82] . Some standard cardiovascular risk prediction algorithms are the Framingham risk score (FRS) [7] , Systematic Coronary Risk Evaluation (SCORE) [8] , American College of Cardiology/American Heart Association (ACC/ AHA) risk score [9] , World Health Organization (WHO) risk charts [83] , and Reynolds's risk score (RRS) [17] . These risk calculators use traditional risk factors such as patient demographics (age, gender, ethnicity), blood biomarkers (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and total cholesterol), behavioral markers (smoking and alcohol consumption), and physiological markers (height, weight, body mass index). All these risk calculators were initially developed for non-RA populations; therefore, when used in RA cohorts, CVD risk is substantially underestimated [10] [11] [12] . The use of traditional risk factors alone (while not considering RA-specific inflammatory markers) could be another reason for such underestimation. However, RRS included an RA-specific inflammatory marker called "high sensitivity C-reactive protein" (hs-CRP) [84] for CVD risk prediction but did not report any significant improvement in the CVD risk assessment [11] . Rajagopalan et al. [85] also reported a small improvement in area under the curve (+ 0.006 in females and + 0.004 in males) when C reactive protein (CRP) or erythrocyte sedimentation rate (ESR) was added to the FRS.

Over the past few years, several efforts have been made to improve the cardiovascular risk assessment in RA patients.

The EULAR guidelines recommended the use of a modified SCORE (mSCORE) in RA patients positive with rheumatoid factor (RF) or anticitrullinated protein antibodies (ACPA) and RA duration of more than 10 years [16, 86] . Cox et al. [19, 20] developed the QRISK2 and QRISK3 algorithms, which use the presence of RA as a CVD risk predictor (hazard ratio = 1.23, 95% confidence interval 1.19-1.28). Solomon et al. [18] also developed an RA-specific CVD risk calculator (called expanded risk score or ERS) by including RA-specific biomarkers [such as disease activity, disease duration, a modified health assessment questionnaire (HAQ) disability index, and daily prednisone use] with the traditional biomarkers used in the Cox-based model. The authors reported an improvement of ~ 4.8% in c-index when validating the risk score on the reserved dataset. Recently, Curtis et al. [87] also proposed a CVD risk prediction tool for RA patients by combining conventional and RA-specific risk factors. The authors predicted the risk of composite CVD events such as MI, stroke, and death during the follow-up period of 3 years. The area under the curve (AUC) for cardiovascular risk stratification for this model was 0.70.

All these RA-specific CVD risk scores reported a better risk assessment on the proprietary databases. Still, when compared with other risk calculators in different RA cohorts, these calculators have demonstrated mixed results [10] [11] [12] . Crowson et al. [11] reported an underestimation of CVD risk by FRS and RRS in 525 RA patients. The observed risk was twice the predicted risk. Furthermore, the authors did not report any improvement in cardiovascular risk prediction when CRP was added to their model. Arts et al. [10] investigated the roles of SCORE, FRS, RRS, and QRISK2 in 1050 RA patients. Out of these four models, SCORE, FRS, and RRS underestimated CVD risk in RA patients, whereas, the QRISK2 reported an overestimation. The AUC ranged between 0.78 and 0.80 for the four risk models. A similar study by Arts et al. [12] investigated the performance of the original, recalibrated, and improved version of SCORE calculators to predict the CVD risk in 1016 RA patients. The AUC values for these scores were 0.78 (95% CI 0.74-0.82), 0.78 (0.74-0.83), and 0.80 (0.75-0.84). All these three scores underestimated the CVD risk in RA patients. In short, even after the SCORE was redesigned using the RA-based risk factors, it did not result in an adequate CVD risk assessment. In another study by Crowson et al. [21] of 5638 RA patients, a CVD-risk prediction model was developed that reported better performance (AUC = 0.71) compared with conventional risk calculators such as FRS (AUC = 0.71), ACC/AHA (AUC = 0.72), SCORE (AUC = 0.70), and QRISK2 (AUC = 0.72). Furthermore, conventional risk calculators either overestimated or underestimated CVD risk in RA patients. Wahlin et al. [88] compared the expanded risk score, ACC/AHA risk score, and a modified version of ACC/ AHA with a multiplier of 1.5 for a CVD risk assessment of 665 RA patients. The authors also reported an underestimation of CVD risk by all calculators. However, the discrimination ability was slightly better, since AUC for ERS-RA risk was 0.78 compared to AUC of 0.98 for two variants of ACC/AHA.

The overall trend of all these risk prediction algorithms, developed for general and RA cohorts, indicates a "poor CVD risk assessment" in patients with RA. One possible reason for such poor performance is the paradoxical behavior of some of the risk factors such as lipids and body mass index. Another potential reason for this outcome is the inclusion of risk factors that do not provide complete information about the CVD risk profile in RA patients [89] . Corrales et al. [89] indicated a high prevalence of carotid atherosclerosis plaque in patients with low-CVD risk. This observation demonstrated the limited ability of conventional risk factor-based algorithms to improve the CVD risk assessment process, which may be improved using imaging modalities. Therefore, there is still room to develop more accurate, automated, and reliable risk calculators for RA patients by exploring and including nontraditional risk factors such as genetic biomarkers, inflammatory biomarkers, or image-based atherosclerotic plaque phenotypes in the risk prediction algorithm.

Imaging modalities are becoming essential for the visualization of atherosclerotic plaque and CVD risk assessment in RA patients [90] . Non-invasive imaging modalities such as computed tomography, magnetic resonance imaging, ultrasound, and positron emission tomography are currently used to assess carotid atherosclerosis in RA patients [26] . MRI is used to measure the plaque composition, including calcification, lipid-rich necrotic core, and fibrous cap thickness [26] . Computed tomography is generally used to determine carotid artery stenosis [27] . F-fludeoxyglucose-positron emission tomography (FDG-PET) is a nuclear imaging modality that quantifies the inflammation in carotid atherosclerotic plaque [91] . Non-invasive carotid ultrasound is a commonly adopted imaging modality that can capture morphological variations in the atherosclerotic plaque quantified using (1) carotid intima-media thickness (cIMT), (2) carotid intima-media thickness variability (IMTV), and (3) plaque area [30] . When compared with other non-invasive counterparts, carotid ultrasound is less expensive and easier to use [30, 92] . Therefore, the scope of this review is restricted to the use of carotid ultrasound for CVD risk assessment in RA patients. The automated cIMT and carotid PA are considered surrogate markers of coronary artery disease and widely used for CVD/stroke risk assessment [31] [32] [33] [34] .

Several studies have shown a high prevalence of increased cIMT and carotid plaque in RA patients [39] [40] [41] . Studies have also demonstrated the significant association between these carotid atherosclerosis biomarkers and RA-specific markers of inflammation, such as ESR, CRP, and IL-6 [35] [36] [37] [38] . Table 1 provides some of such studies that link both carotid atherosclerosis and RA, using two sets of biomarkers (i.e., image-based phenotypes and inflammatory biomarkers). One common observation from these studies is that patients with RA show an elevated cIMT and carotid plaque area compared with non-RA cohorts (row R2-R4 of Table 1 ) [39, 40, 93] . This association between carotid atherosclerosis and RA also seems independent of the three carotid artery segments (common carotid artery, carotid bulb, and internal carotid artery) from where the cIMT or plaque was measured [40, 93] . However, several studies have reported more aggressive atherosclerotic plaque formation in the carotid bulb segment when compared to other arterial segments [94] . The higher plaque prevalence in the carotid bulb is a consequence of turbulent blood flow and reduced shear stress, which leads to endothelial dysfunction [95, 96] . This observation of higher plaque in a bulb has also been confirmed in RA patients [40] . Figure 3 shows carotid ultrasound scans for RA (Fig. 3a, b) and non-RA patients (Fig. 3c, d) . The left-hand side panel of Fig. 3a , c shows the raw carotid ultrasound scans measured using a B-mode ultrasound scanner.

Similarly, the right-hand side panels of Fig. 3b , d show the processed scans tracking morphological variations in the carotid atherosclerotic plaque for the quantification of cIMT and plaque area. The cIMT and plaque area are both greater in RA patients than in non-RA patients.

Another important observation from Table 1 is the significant association between carotid atherosclerotic biomarkers and RA-specific inflammatory markers, such as ESR, CRP, and IL-6 [37, 97]. ESR is a relatively inexpensive measure of inflammation in RA patients-therefore, several studies have used ESR for CVD risk assessment [98] [99] [100] . Some of such studies are listed in Table 2 . All these studies indicated a substantially higher CVD event rate in patients with elevated ESR levels. Besides ESR, studies have also suggested the use of other popular RA-specific inflammatory markers such as CRP, or hsCRP, and IL-6 for the improvement in the CVD risk assessment [37, 85, 101, 102] . Furthermore, these RA-specific inflammatory markers are also associated with the annual progression of cIMT [38, 97, [103] [104] [105] , which is a prominent surrogate marker of cardiovascular events. In a study with 30 RA patients, Kaseem et al.

[37] demonstrated the association of ESR, CRP, and IL-6 with carotid atherosclerosis, with significant odds ratios (p < 0.05) of 1.50, 1.90, and 1.80, respectively.

The broad usage of carotid ultrasound-based phenotypes and their significant association with RA-specific inflammatory markers has also enabled their inclusion in the CVD risk prediction calculators [42, 43, 54, 106] .

Recently, several CVD/stroke risk prediction models have been developed that have combined the effect of conventional risk factors and the automated carotid atherosclerosis biomarkers [42, 43] . These risk prediction models reported a better performance in identifying high CVD risk patients compared with current standard-of-care risk calculators. However, such so-called integrated risk prediction models were developed for the general population. They were based on the annual progression rates of carotid atherosclerotic biomarkers and conventional risk factors [42] [43] [44] . Therefore, given the progression rates of cIMT and PA due to the RAspecific inflammatory markers, such models can be updated and might be useful for CVD risk assessment in RA patients.

Artificial intelligence (AI) is expeditiously changing the landscape of the global healthcare system and assisting the healthcare workforce in clinical decision-making [107] . Machine learning (ML) and deep learning (DL) are the two common branches of AI that have broad ranges of applications in almost every medical imaging sector (e.g., classification and plaque characterization for stroke risk assessment [47] , thyroid cancer characterization [48] , liver cancer diagnosis [49] , prostate cancer diagnosis, ovarian cancer diagnosis [53] , lung cancer detection [108] , brain tumor classification [50] , and heart disease prediction and disease classification [51, 52, 54] ). During the recent global pandemic of coronavirus diseases 2019, AI is providing promising results in the diagnosis of patients with the help of several imaging techniques such as computed tomography [109] and X-rays [110] . Since this review is on CVD/stroke risk assessment, we have summarized several studies that have used ML-based algorithms for CVD/stroke risk assessment ( Table 3) . All of these studies follow a supervised learning approach in which the ML-based classifier is trained to identify the correct output labels using input risk factors or features and predefined gold standards or labels. Figure 4 shows the generalized framework of supervised ML-based CVD risk assessment. In the case of CVD risk assessment, the gold standard can be (1) the primary endpoints such as presence or absence of cardiovascular events, or (2) surrogate endpoints such as cIMT, PA, and CAC score, or a combination of these risk factors [51, 52, 54] . Several types of input features can be used to train the AI-based algorithms. They can be traditional risk factors, image-based phenotypes, grayscale image features, or statistically derived features. Once the offline ML classifier is trained using these features and gold standard, its coefficients are then used in the online ML system to predict the out risk labels. Online ML systems do not require a gold standard to make the final risk classification. All the studies provided in Table 3 used this approach for CVD risk assessment. Unlike ML-based algorithms, DLbased models, such as convolutional neural networks, do not require input features beforehand. Instead, such algorithms automatically learn their offline coefficients from the input image datasets [111] . Currently, AI-based techniques are used in the diagnosis of RA [57] , the identification of RA disease severity [58] , the classification of several RA synovial tissues [59] , and mortality prediction due to RA [60] . Although ML-based algorithms are used in the RA field, no efforts have been made to assess the CVD risk in RA patients using such automated intelligence-based paradigms. ML-based algorithms have been used to perform CVD risk assessments in non-RA populations and reported a better performance in identifying high-risk CVD patients when compared with the current standard of care conventional risk calculators [51, 55, 56] . Patients with RA experience more atherosclerotic plaque in the carotid artery, which might lead to cardiovascular events [39] [40] [41] . In recent years several studies have demonstrated a better stroke risk assessment using ML-based strategies [29] and DL-based strategies [112] . Besides all these studies, attempts can be made to develop more accurate CVD risk prediction tools for RA patients using AI techniques. Figure 5 conceptualizes several components required for CVD risk assessment in RA patients. The AI-based CVD risk assessment for RA patients can be made possible by combining several types of risk factors, such as patients' demographics, physiological parameters, behavioral risk factors, image-based phenotypes, and (most importantly) RA-specific inflammatory markers. This combined set of features can be used as inputs along with the gold standard to identify what CVD risk category RA patients belong to. As such, both ML and DL-based systems can be employed to performed CVD risk assessment in patients. Because of the significant association between carotid atherosclerosis and RA, researchers can conduct a pilot study with cIMT and plaque areas as the surrogate markers for CVD risk assessment.

In this review, we provided several pathophysiological pathways that highlight the role of cardiovascular and inflammatory risk factors in the progression of atherosclerosis and heart injury in RA patients. Furthermore, we also indicated an unmet need to look for new biomarkers to achieve a more accurate cardiovascular risk assessment in RA patients. Specifically, carotid ultrasound is a non-invasive and economical technique for preventive screening applications. The carotid atherosclerotic image-based biomarkers such as cIMT and plaque have a significant association with RA-specific inflammatory markers. Most of the current statistically derived cardiovascular risk calculators, developed for both RA and non-RA cohorts, either underestimate or overestimate the CVD risk in RA patients. Even after the inclusion of RA-specific inflammatory markers such as CRP, risk calculators reported little improvement in risk prediction. The accuracy of risk assessment can be improved using AI techniques. AI techniques are currently used for RA screening and not for CVD risk assessment in RA patients. However, they reported promising results of CVD risk assessment in non-RA cohorts. Thus, we believe that the development of AI-driven risk prediction models by combining traditional, image-based, and inflammatory risk factors is warranted to improve the CVD risk assessment in RA patients. There was a small improvement in CVD prediction when ESR or CRP was added to the Framingham model 

Extra-articular manifestations in rheumatoid arthritis

The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study

Sex differences in rheumatoid arthritis: more than meets the eye

Rheumatoid arthritis and cardiovascular disease

High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines

Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis

Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis

Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms

Del Rincón I (2005) Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation

Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies

Nurmohamed MT (2016) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score

Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study

Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study

Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2

Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis

Arthritis AT-ACCfR (2017) Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries

Rheumatoid arthritis: atherosclerosis imaging and cardiovascular risk assessment using machine and deep learning-based tissue characterization

Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis

Atherosclerosis in rheumatoid arthtritis: the role of high-resolution B mode ultrasound in the measurement of the arterial intima-media thickness

Increased prevalence of carotid artery atherosclerosis in rheumatoid arthritis is artery-specific

Do carotid artery diameters manifest early evidence of atherosclerosis in women with rheumatoid arthritis?

Integration of eGFR biomarker in image-based CV/stroke risk calculator: a south Asian-Indian diabetes cohort with moderate chronic kidney disease

Effect of carotid image-based phenotypes on cardiovascular risk calculator: AECRS1. 0

Nonlinear model for the carotid artery disease 10-year risk prediction by fusing conventional cardiovascular factors to carotid ultrasound image phenotypes: a Japanese diabetes cohort study

Performance evaluation of 10-year ultrasound image-based stroke/cardiovascular (CV) risk calculator by comparing against ten conventional CV risk calculators: a diabetic study

The present and future of deep learning in radiology

Stroke risk stratification and its validation using ultrasonic Echolucent Carotid Wall plaque morphology: a machine learning paradigm

A review on ultrasound-based thyroid cancer tissue characterization and automated classification

Automated stratification of liver disease in ultrasound: an online accurate feature classification paradigm

A review on a deep learning perspective in brain cancer classification

2020) Cardiovascular/stroke risk predictive calculators: a comparison between statistical and machine learning models

Ultrasound-based stroke/cardiovascular risk stratification using Framingham Risk Score and ASCVD Risk Score based on "Integrated Vascular Age" instead of

In-vitro and in vivo diagnostic techniques for prostate cancer: a review

A low-cost machine learning-based cardiovascular/stroke risk assessment system: integration of conventional factors with image phenotypes

Machine learning outperforms ACC/ AHA CVD risk calculator in MESA

Can machine-learning improve cardiovascular risk prediction using routine clinical data

Defining disease phenotypes in primary care electronic health records by a machine learning approach: a case study in identifying rheumatoid arthritis

Automatic prediction of rheumatoid arthritis disease activity from the electronic medical records

Identification of three rheumatoid arthritis disease subtypes by machine learning integration of synovial histologic features and RNA sequencing data

Development and validation of a multivariate predictive model for rheumatoid arthritis mortality using a machine learning approach

Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis

The physiology and pathophysiology of the nitric oxide/superoxide system

Interaction between hypertension and arterial stiffness: an expert reappraisal

Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research

Hypertension in rheumatoid arthritis

Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis

Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors

Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?

Rheumatoid cachexia and cardiovascular disease

Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions

NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia

Rheumatoid cachexia: the undiagnosed, untreated key to restoring physical function in rheumatoid arthritis patients

Rheumatoid cachexia, central obesity and malnutrition in patients with low-active rheumatoid arthritis: feasibility of anthropometry, Mini Nutritional Assessment and body composition techniques

Underweight and obese states both associate with worse disease activity and physical function in patients with established rheumatoid arthritis

Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity

Insulin resistance in early untreated rheumatoid arthritis patients

Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes

Role of insulin resistance in increased frequency of atherosclerosis detected by carotid ultrasonography in rheumatoid arthritis

Inflammation and cardiovascular disease mechanisms

Cardiovascular risk assessment and lipid modification: NICE guideline

Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult

World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries

C-reactive protein as a cardiovascular risk factor

SAT0069 performance of the Framingham Cardiovascular risk prediction model with and without C-reactive protein or erythrocyte sedimentation rate in RA: analysis of US electronic medical records database

update of the ASAS-EULAR management recommendations for axial spondyloarthritis

Development and validation of a biomarker-based cardiovascular risk prediction score in rheumatoid arthritis

Performance of the expanded cardiovascular risk prediction score for rheumatoid arthritis is not superior to the ACC/AHA Risk calculator

Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study

The role of non-invasive cardiovascular imaging in the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to be

A pilot trial to examine the changes in carotid arterial inflammation in renal transplant recipients as assessed by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography computed tomography (PET/CT)

Low-cost preventive screening using carotid ultrasound in patients with diabetes

Rheumatoid arthritis is an independent risk factor for increased carotid intima-media thickness: impact of anti-inflammatory treatment

Does the carotid bulb offer a better 10-year CVD/stroke risk assessment compared with the common carotid artery?: a 1516 ultrasound scan study

The plasma protein profile and cardiovascular risk differ between intima-media thickness of the common carotid artery and the bulb: a meta-analysis and a longitudinal evaluation

Relationship between carotid artery atherosclerosis and bulb geometry

Association of interleukin-6 with the progression of carotid atherosclerosis: a 9-year follow-up study

Erythrocyte sedimentation rate as a marker for coronary heart disease

Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women: the Reykjavik Study

Erythrocyte sedimentation rate, coronary atherosclerosis, and cardiac mortality

Increased high-sensitivity C-reactive protein, erythrocyte sedimentation rate and lactic acid in stroke patients with internal carotid artery occlusion

ESR rate can be a marker for coronary artery disease

Combined effects of hemoglobin A1c and C-reactive protein on the progression of subclinical carotid atherosclerosis: the INVADE study

C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study

C-reactive protein is an independent predictor for carotid artery intima-media thickness progression in asymptomatic younger adults (from the Bogalusa Heart Study)

Carotid intimamedia thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study

State-of-the-art review on deep learning in medical imaging

Lung imaging and computer aided diagnosis

Artificial intelligence distinguishes COVID-19 from community acquired pneumonia on chest CT

Detection of Covid-19 from chest X-ray images using artificial intelligence: an early review. arXiv preprint arXiv

Deep learning fully convolution network for lumen characterization in diabetic patients using carotid ultrasound: a tool for stroke risk

Ultrasound-based carotid plaque tissue risk stratification using 3-D optimized artificial intelligence paradigm: a cardiovascular/ stroke application: atheromatic 2.0

Associations between coronary and carotid artery atherosclerosis in patients with inflammatory joint diseases

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

Prognostic value of erythrocyte sedimentation rate in ST segment elevation myocardial infarction: interaction with hyperglycaemia

A novel computerized tool to stratify risk in carotid atherosclerosis using kinematic features of the arterial wall

Development of health parameter model for risk prediction of CVD using SVM

Cardiovascular event prediction by machine learning: the Multi-Ethnic Study of Atherosclerosis

Wall-based measurement features provides an improved IVUS coronary artery risk assessment when fused with plaque texture-based features during machine learning paradigm

Cardiovascular/stroke risk prevention: a new machine learning framework integrating carotid ultrasound image-based phenotypes and its harmonics with conventional risk factors

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Conflict of interest The author(s) declare that they have no competing interests.

Ankush D. Jamthikar 1 · Deep Gupta 1 · Anudeep Puvvula 2 · Amer M. Johri 3 · Narendra N. Khanna 4 · Luca Saba 5 · Sophie Mavrogeni 6 · John R. Laird 7 · Gyan Pareek 8 · Martin Miner 9 · Petros P. Sfikakis 10 · Athanasios Protogerou 11 · George D. Kitas 12 · Raghu Kolluri 13 · Aditya M. Sharma 14